AstraZeneca lung and breast cancer data at WCLC and ESMO 2021 underscore ambition to revolutionise outcomes for patients
- Date 3 Sep 2021
Enhertu demonstrates transformative progression-free survival in HER2-positive metastatic breast cancer; data in lung and gastric cancers show strong efficacy across HER2-targetable tumours.
Multiple trials reinforce the efficacy of Imfinzi combinations, including with novel immunotherapies, for lung cancer patients across settings
AstraZeneca will present new data across its diverse portfolio of cancer medicines at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Congress 2021.
You might also be interested in these articles
MicrosensDx collaborates with Imperial researchers to develop groundbreaking sepsis test
Wed 25 Sep 2024
Cambridge Science Centre Welcomes Brockton Everlast as New Executive Council Member New Three-Year Partnership to Develop Innovative Programme on the Built Environment
Wed 25 Sep 2024
VeriPark Joins the Cambridge Science Park Community
Thu 19 Sep 2024
